Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound βE/β0-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The βE-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated βE-globin with partial instability. When this is compounded with a non-functional β0 allele, a profound decrease in β-globin synthesis results, and approximately half of βE/β0-thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl−1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-bia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, this response was associated with a relative increase in a dominant myeloid clone bearing a lentiviral vector insertion within the HMGA2 gene locus.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“In the initial study of HSCs transduced with β-globin in patients with β-thalassemia, one patient with βE/β0-thalassemia achieved independence from transfusion [67].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“The relative clonal dominance at the HMGA2 locus that was initially observed in 1 patient in the LG001 study of the HPV569 vector spontaneously subsided while that patient maintained stable HbA T87Q levels.”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
In the citing paper
“The feasibility of the addition of a gene to autologous hematopoietic cells using a lentiviral vector was shown previously in a single patient with β-thalassemia who safely discontinued transfusions for more than 6 years with ongoing, sustained β A-T87Q -globin expression.14,20”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
MicroRNA maturation: stepwise processing and subcellular localization
Lee, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf476 · Cited by 2,478
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“To demonstrate that only one integrated vector provirus was present in cells with the HMGA2 IS, three qPCR experiments were simultaneously performed on the same genomic DNA preparation with primers specific for either (1) a ‘HIV gag packaging signal’ DNA sequence (common to all vector provirus regardless of IS); (2) t…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Lin28 promotes transformation and is associated with advanced human malignancies
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L. A., Lockhart, V. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.392 · Cited by 814
Long-Term Propagation of Distinct Hematopoietic Differentiation Programs In Vivo
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.-J., Brinkman, R., & Eaves, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.015 · Cited by 609
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
Background
Cited by
Items 401–500 of 1,000
Uchida, N., Nassehi, T., Drysdale, C. M., Gamer, J., Yapundich, M., Bonifacino, A. C., Krouse, A. E., Linde, N. S., Hsieh, M. M., Donahue, R. E., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.022 · Cited by 40
“INTRODUCTION Hematopoietic stem cell (HSC)-targeted gene therapy is curative for several immunodeficiencies and is under development for hemoglobin disorders, including sickle cell disease (SCD).(6,7) In current HSC gene-therapy strategies, a therapeutic gene is added to CD34 cells by means of a lentiviral vector, and…”
BackgroundHematopoietic Stem Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies
Drysdale, C. M., Nassehi, T., Gamer, J., Yapundich, M., Tisdale, J. F., & Uchida, N. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.001 · Cited by 44
Retroviral gene therapy in Germany with a view on previous experience and future perspectives
Morgan, M. A., Galla, M., Grez, M., Fehse, B., & Schambach, A. (2021) · Gene Therapy · doi:10.1038/s41434-021-00237-x · Cited by 42
Gene therapy for metabolic diseases
Chandler, R. J., & Venditti, C. P. (2016) · Translational Science of Rare Diseases · doi:10.3233/trd-160007 · Cited by 42
Development of Gene Therapy for Thalassemia
Nienhuis, A. W., & Persons, D. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011833 · Cited by 38
“To date, three participants have been enrolled on the clinical trial, which is open in Paris (Cavazzana-Calvo et al. 2010; P Leboulch, pers. comm.).”
BackgroundInfluentialGene therapy for sickle cell disease: recent advances, clinical trials and future directions
Ballantine, J., & Tisdale, J. F. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.11.006 · Cited by 42
Urbinati, F., Hargrove, P. W., Geiger, S., Romero, Z. G., Wherley, J., Kaufman, M. L., Hollis, R. P., Chambers, C. B., Persons, D. A., Kohn, D. B., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.01.009 · Cited by 40
Pharmacological and molecular approaches for the treatment of β‐hemoglobin disorders
Lohani, N., Bhargava, N., Munshi, A., & Ramalingam, S. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26292 · Cited by 40
“…of gene therapy for β-thalassemia were started, one based on the vector BB305, a variant of βT87Q/HVP569 (LG001) (Bank, Dorazio, & Leboulch, 2005; Cavazzana-Calvo et al., 2010; Cavazzana, Antoniani, Miccio, 2017), which is sponsored by Massachusetts based Biotechnology company, Bluebird Bio,…”
RNA Therapeutics: Delivery Problems and Solutions—A Review
Pozdniakova, N. V., Generalov, E. A., Shevelev, A. B., & Tarasova, O. A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101305 · Cited by 41
“At present, there are practically no perspectives for introducing such vectors into practice for safety reasons [202].”
Therapeutic Potential of MicroRNA Let-7: Tumor Suppression or Impeding Normal Stemness
Chiu, S., Chung, H.-Y., Cho, D., Chan, T.-M., Liu, M.-C., Huang, H.-M., Li, T.-Y., Lin, J.-Y., Chou, P.-C., Fu, R., et al. (2014) · Cell Transplantation · doi:10.3727/096368914x678418 · Cited by 41
Advancing Polymeric Delivery Systems Amidst a Nucleic Acid Therapy Renaissance
Burke, P. A., Pun, S. H., & Reineke, T. M. (2013) · ACS Macro Letters · doi:10.1021/mz400418j · Cited by 44
CRISPR ‐Cas9 technology and its application in haematological disorders
Zhang, H., & McCarty, N. (2016) · British Journal of Haematology · doi:10.1111/bjh.14297 · Cited by 44
UM171 Enhances Lentiviral Gene Transfer and Recovery of Primitive Human Hematopoietic Cells
Ngom, M., Imren, S., Maetzig, T., Adair, J. E., Knapp, D. J. H. F., Chagraoui, J., Fares, I., Bordeleau, M.-È., Sauvageau, G., Leboulch, P., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.009 · Cited by 40
Self-citationStrategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges
Yoder, K. E., Rabe, A. J., Fishel, R. A., & Larue, R. C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.662331 · Cited by 41
Targeting matrix metalloproteinase MMP3 greatly enhances oncolytic virus mediated tumor therapy
Liang, M., Wang, J., Wu, C., Wu, M., Hu, J., Dai, J., Ruan, H., Xiong, S., & Dong, C. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101221 · Cited by 39
Aiuti, A., Cossu, G., de Felipe, P., Galli, M. C., Narayanan, G., Renner, M., Stahlbom, A., Schneider, C. K., & Voltz-Girolt, C. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.119 · Cited by 35
“…adverse events were restricted to some gammaretroviral-based clinical trials, in a beta-thalassemia patient treated by lentiviral-vector-based gene therapy, the appearance of a self-limiting dominant clone in the myeloid compartment of a patient raised some concern (Cavazzana-Calvo et al. , 2010).”
A snapshot of biologic drug development: Challenges and opportunities
Andrews, L., Ralston, S. L., Blomme, E. A. G., & Barnhart, K. F. (2015) · Human & Experimental Toxicology · doi:10.1177/0960327115603594 · Cited by 47
Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9
Amiri, M., Moaveni, A. K., Zolbin, M. M., Shademan, B., & Nourazarian, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462697 · Cited by 42
Su, L., Deng, Z., & Leng, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103710 · Cited by 39
“with β-globin lentiviral vector were transplanted into the patient’s bone morrow [111].”
BackgroundMethodInfluentialMolecular Medicine: Found in Translation
Orkin, S. H. (2021) · Med · doi:10.1016/j.medj.2020.12.011 · Cited by 39
Uchida, N., Hargrove, P. W., Lap, C. J., Evans, M. E., Phang, O., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Nguyen, A.-D., Hsieh, M. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.159 · Cited by 36
Bauer, T. R., Tuschong, L. M., Calvo, K. R., Shive, H. R., Burkholder, T. H., Karlsson, E. K., West, R. R., Russell, D. W., & Hickstein, D. D. (2013) · Molecular Therapy · doi:10.1038/mt.2013.34 · Cited by 37
Aerosol gene delivery using viral vectors and cationic carriers forin vivolung cancer therapy
Hong, S., Park, S. J., Lee, S., Cho, C. S., & Cho, M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.986454 · Cited by 43
“In addition to these animal experiments, many clinical trials using lentiviral vectors have shown successful results [19-22].”
BackgroundT-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities
Hu, J., & Dunbar, C. E. (2024) · Blood · doi:10.1182/blood.2024025828 · Cited by 37
Murakami, Y., Inoue, N., Shichishima, T., Ohta, R., Noji, H., Maeda, Y., Nishimura, J., Kanakura, Y., & Kinoshita, T. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08914.x · Cited by 35
Current progress on gene therapy for primary immunodeficiencies
Zhang, L., Thrasher, A. J., & Gaspar, H. B. (2013) · Gene Therapy · doi:10.1038/gt.2013.21 · Cited by 40
Alpharetroviral Vectors: From a Cancer-Causing Agent to a Useful Tool for Human Gene Therapy
Suerth, J. D., Labenski, V., & Schambach, A. (2014) · Viruses · doi:10.3390/v6124811 · Cited by 39
“removal of splice sites from the vector, as these sites can lead to aberrant splicing events and are frequently involved in gene transcript truncations [27–29].”
BackgroundCornetta, K. G., Lin, T., Pellin, D., & Kohn, D. B. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.11.009 · Cited by 40
“reported a clonal expansion of erythroid progenitors in a patient treated with a lentiviral vector for thalassemia.(32) In this case, a vector integrant within an intron of the HMGA2 gene led to splicing of the HMGA2 transcript to a cryptic splice site in an insulator element in the LTR.”
BackgroundSelf-citationHematopoietic stem cell expansion and gene therapy
Watts, K. L., Adair, J. E., & Kiem, H. (2011) · Cytotherapy · doi:10.3109/14653249.2011.620748 · Cited by 35
“Cavazzana-Calvo et al. (10) have shown transfusion independence of a patient with severe β -thalassemia nearly 3 years after transplantation with gene-corrected autologous HSC. Hitherto, this disorder has been diffi cult to treat with gene therapy because of the need for substantial hemoglobin…”
Koblas, T., Leontovyc, I., Loukotova, S., Kosinova, L., & Saudek, F. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.33 · Cited by 35
Synthetic Biology—Toward Therapeutic Solutions
Haellman, V., & Fussenegger, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.08.020 · Cited by 36
HIV-derived vectors for therapy and vaccination against HIV
Nunzio, F. D., Félix, T., Arhel, N. J., Nisole, S., Charneau, P., & Beignon, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.089 · Cited by 38
“Vector integration near the MGA2 gene resulted in its transcriptional activation in erythroid ells and despite the presence of a cHS4 chromatin insulator in he U3 region [32].”
Liu, R., Zhao, W., Zhao, Q., Liu, S., Liu, J., He, M., Xu, Y. X. Z., Wang, W., Liu, W., Xia, Q., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8681-1 · Cited by 35
Microfluidic Transduction Harnesses Mass Transport Principles to Enhance Gene Transfer Efficiency
Tran, R., Myers, D. R., Denning, G., Shields, J. E., Lytle, A. M., Alrowais, H., Qiu, Y., Sakurai, Y., Li, W. C., Brand, O., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.002 · Cited by 36
Gene therapy and gene editing strategies for hemoglobinopathies
Lidonnici, M. R., & Ferrari, G. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.12.001 · Cited by 36
Solving the Problem of γ-Retroviral Vectors Containing Long Terminal Repeats
Persons, D. A., & Baum, C. (2011) · Molecular Therapy · doi:10.1038/mt.2010.305 · Cited by 33
Efficient Large Volume Lentiviral Vector Production Using Flow Electroporation
Witting, S. R., Li, L.-H., Jasti, A. C., Allen, C., Cornetta, K. G., Brady, J. P., Shivakumar, R., & Peshwa, M. V. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.088 · Cited by 37
“A phase I clinical trial using lentiviruses to treat HIV (Levine et al., 2006) and a recent report showing transfusion independence in a b-thalassemia patient (Cavazzana-Calvo et al., 2010) illustrate these vectors’ utility in clinical applications.”
BackgroundSelf-citationIn mixed hematopoietic chimerism, the donor red cells win
Hsieh, M., Wu, C. J., & Tisdale, J. F. (2010) · Haematologica · doi:10.3324/haematol.2010.035576 · Cited by 34
“By 2 years after therapy, the genetically modified cells accounted for 11% of peripheral blood leukocytes (18% granulocyte-monocytes), 11% of marrow erythroid colonies and 13% of marrow myeloid colonies.(17) Collectively, these observations support mixed hematopoietic chimerism as a rational goal in non-malignant diso…”
BackgroundJohnston, J. M., Denning, G., Doering, C. B., & Spencer, H. T. (2012) · Gene Therapy · doi:10.1038/gt.2012.76 · Cited by 34
Animal models of β-hemoglobinopathies: utility and limitations
McColl, B., & Vadolas, J. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s87955 · Cited by 37
“Such vectors have now passed into human trials, where they have achieved relief of acute and chronic symptoms of β-thalassemia and long-term transfusion independence.(70,71) Further trials in β-thalassemia and SCD patients are ongoing.”
Kaufmann, K. B., Brendel, C., Suerth, J. D., Müller-Kuller, U., Chen-Wichmann, L., Schwäble, J., Pahujani, S., Kunkel, H., Schambach, A., Baum, C., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.249 · Cited by 36
Ozog, S., Timberlake, N. D., Hermann, K. J., Garijo, O., Haworth, K. G., Shi, G., Glinkerman, C. M., Schefter, L. E., D'Souza, S. S., Simpson, E., et al. (2019) · Blood · doi:10.1182/blood.2019000040 · Cited by 33
Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders
Uchida, N., Hsieh, M. M., Raines, L. N., Haro‐Mora, J. J., Demirci, S., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2019) · Nature Communications · doi:10.1038/s41467-019-12456-3 · Cited by 34
Lentiviral Vector Production from a Stable Packaging Cell Line Using a Packed Bed Bioreactor
Powers, A. D., Drury, J. E., Hoehamer, C. F., Lockey, T. D., & Meagher, M. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.010 · Cited by 35
Brault, J., Liu, T., Liu, S., Lawson, A., Choi, U., Kozhushko, N., Bzhilyanskaya, V., Pavel-Dinu, M., Meis, R. J., Eckhaus, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1067417 · Cited by 38
“Frontiers in Immunology 12 Preferential LV insertion in coding regions heightens risk for aberrant fusion transcripts between vector and insertion gene have resulted in clonal HMGA2 expansions in b-Thalassemia and XSCID (10, 11).”
BackgroundBarese, C. N., Felizardo, T. C., Sellers, S. E., Keyvanfar, K., Stasi, A. D., Metzger, M. E., Krouse, A. E., Donahue, R. E., Spencer, D. M., & Dunbar, C. E. (2014) · Stem Cells · doi:10.1002/stem.1869 · Cited by 35
Cell and Gene Therapy for Friedreich Ataxia: Progress to Date
Evans‐Galea, M. V., Pébay, A., Dottori, M., Corben, L. A., Ong, S. H., Lockhart, P. J., & Delatycki, M. B. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.180 · Cited by 41
Integration of retroviral vectors
Gabriel, R., Schmidt, M., & Kalle, C. V. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.006 · Cited by 39
“Indeed, in the beta-thalassaemia trial a clonal expansion has been attributed to vector integration induced expression of a truncated HMGA2 transcript [51].”
BackgroundMethodUchida, N., Fujita, A., Hsieh, M. M., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.029 · Cited by 34
“3,6,7 13–16 iPS cell–based regenerative therapy is also very attractive, since iPS cells can be generated from virtually any cell type in SCD patients.”
Skeate, J. G., Pomeroy, E. J., Slipek, N. J., Jones, B. J., Wick, B. J., Chang, J., Lahr, W. S., Stelljes, E. M., Patrinostro, X., Barnes, B., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.024 · Cited by 34
“10,20,24 A novel representative of the hAT superfamily of transposons is TcBuster , originally isolated from the red fl our beetle.”
Progress in gene therapy for primary immunodeficiencies using lentiviral vectors
Sauer, A. V., Lorenzo, B. D., Carriglio, N., & Aiuti, A. (2014) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000114 · Cited by 32
“They may upregulate the expression of genes flanking the integration site when carrying strong enhancer/promoter sequences in internal positions [1,2,19,80,81] or induce aberrant splicing and/or premature termination of endogenous transcripts of the targeted gene and cause loss-of-function or gain-offunction mutations…”
BackgroundThumann, G., Harmening, N., Prat-Souteyrand, C., Marie, C., Pastor, M., Sebe, A., Miskey, C., Hurst, L. D., Diarra, S., Kropp, M., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.02.002 · Cited by 33
Advance genome editing technologies in the treatment of human diseases: CRISPR therapy (Review)
Alagöz, M., & Kherad, N. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4609 · Cited by 38
“Furthermore, using modified cells with ZFN does not result in permanent changes in vivo, as modified cells fail to control HIV-1 replication due to the presence of unmodified cells (113).”
Sites of retroviral DNA integration: From basic research to clinical applications
Serrao, E., & Engelman, A. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1102859 · Cited by 36
“…genes like PRDM16, SETBP1, CCND2 and HMGA2 recurrently present in recipient patients, but cell clones harboring these integrations had extensively expanded to dominate over time (Cavazzana-Calvo et al., 2010; Deichmann et al., 2007; Ott et al., 2006; Schwarzwaelder et al., 2007; Wang et al., 2010).”
BackgroundPapanikolaou, E., Kontostathi, G., Drakopoulou, E., Georgomanoli, M., Stamateris, E., Vougas, K., Vlahou, A., Maloy, A., Ware, M., & Anagnou, N. P. (2013) · Virus Research · doi:10.1016/j.virusres.2013.03.015 · Cited by 34
Goyal, S., Kim, S., Chen, I. S. Y., & Chou, T. (2015) · BMC Biology · doi:10.1186/s12915-015-0191-8 · Cited by 35
“Such studies in humans [15] have revealed highly complex polyclonal repopulation that is supported by tens of thousands of different clones [15–18]; a clone is defined as a population of cells of the same lineage, identified here by a unique VIS.”
BackgroundTorres‐Torronteras, J., Cabrera-Pérez, R., Barba, I., Costa, C., de Luna, N., Andreu, A. L., Barquinero, J., Hirano, M., Cámara, Y., & Martí, R. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.160 · Cited by 33
Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods
Javaid, N., Yasmeen, F., & Choi, S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090441 · Cited by 36
“Nowadays, fruitful results are obtained in clinical trials on different diseases including Parkinson’s disease [8], Leber’s amaurosis [9], hemophilia B [10], thalassemia [11], hereditary immunodeficiency diseases [12–14], leukodystrophy [15], B-cell cancers, and heart failure [16].”
BackgroundYang, H., Qing, K., Keeler, G. D., Yin, L., Mietzsch, M., Ling, C., Hoffman, B. E., Agbandje‐McKenna, M., Tan, M., Wang, W., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.03.009 · Cited by 32
“Indeed, integration of a lentiviral vector leading to activation of a cellular proto-oncogene, HMGA2, in a patient with b-thalassemia has been reported.(9) Thus, the long-term safety of lentiviral vectors still remains to be determined.”
BackgroundGenome Editing for β-Hemoglobinopathies: Advances and Challenges
Frati, G., & Miccio, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030482 · Cited by 36
Chen, H.-Y., Huang, C., Tian, L., Huang, X., Zhang, C., Llewellyn, G. N., Rogers, G. L., Andresen, K., O’Gorman, M. R. G., Chen, Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00966-21 · Cited by 32
Reichenbach, P., Attianese, G. M. P. G., Ouchen, K., Cribioli, E., Triboulet, M. M., Ash, S., Saillard, M., de Silly, R. V., Coukos, G., & Irving, M. B. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01013-5 · Cited by 33
Evaluation of macrophage-specific promoters using lentiviral delivery in mice
Levin, M. C., Lidberg, U., Jirholt, P., Adiels, M., Wramstedt, A., Gustafsson, K. T., Greaves, D. R., Li, S., Fazio, S., Linton, M. F., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.195 · Cited by 35
Study of Serum Hepcidin in Hereditary Hemolytic Anemias
El-Beshlawy, A. M., Alaraby, I., Kader, M. S. E. M. A., Ahmed, D. H., & Abdelrahman, H. E. M. (2012) · Hemoglobin · doi:10.3109/03630269.2012.721151 · Cited by 31
“Gene therapy approaches that promise more widespread application are under investigation (28).”
BackgroundEngineering Stem Cells for Biomedical Applications
Yin, P. T., Han, E. X., & Lee, K. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400842 · Cited by 32
West, D. B., Engelhard, E. K., Adkisson, M., Nava, A. J., Kirov, J. V., Cipollone, A., Willis, B., Rapp, J., de Jong, P. J., & Lloyd, K. C. K. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005691 · Cited by 34
Gene Therapy for Pompe Disease: The Time is now
Colella, P., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.109 · Cited by 37
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 31
Recent challenges and advances in genetically-engineered cell therapy
Yong, S., Chung, J. Y., Song, Y., & Kim, Y. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0381-1 · Cited by 34
Keller, M. D., Notarangelo, L. D., & Malech, H. L. (2018) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piy011 · Cited by 32
Genetic therapies for the first molecular disease
Doerfler, P. A., Sharma, A., Porter, J. S., Zheng, Y., Tisdale, J. F., & Weiss, M. J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146394 · Cited by 31
“In the HGB-207 (NCT02906202) clinical trial for β-thalassemia, one participant treated with LV gene therapy developed a dominant HSC clone with insertional activation of HMGA2, a DNA-binding protein associated with benign and malignant tumor formation (114).”
BackgroundGene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials
Segura, E., Ayoub, P. G., Hart, K. L., & Kohn, D. B. (2023) · Viruses · doi:10.3390/v15030713 · Cited by 35
Gene therapy for sickle cell disease
Leonard, A. K., & Tisdale, J. F. (2023) · Hematology · doi:10.1182/hematology.2023000487 · Cited by 37
Tubsuwan, A., Abed, S., Deichmann, A., Kardel, M., Bartholomae, C. C., Cheung, A. M. S., Nègre, O., Kadri, Z., Fucharoen, S., Kalle, C. V., et al. (2013) · Stem Cells · doi:10.1002/stem.1436 · Cited by 32
Self-citationHeterogeneity in hematopoietic stem cell populations: implications for transplantation
Miller, P. H., Knapp, D. J. H. F., & Eaves, C. J. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328360aaf6 · Cited by 34
Pigeon, L., Gonçalves, C., Gosset, D., Pichon, C., & Midoux, P. (2013) · Small · doi:10.1002/smll.201300217 · Cited by 31
Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges
Ghiaccio, V., Chappell, M., Rivella, S., & Breda, L. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00383-4 · Cited by 31
“This element was subsequently dismissed due to loss of such element at the boundaries of the transgene after integration and loss of titer [45, 46].”
BackgroundGenome editing approaches to β-hemoglobinopathies
Brusson, M., & Miccio, A. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.025 · Cited by 33
Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major
Santarone, S., Angelini, S., Natale, A., Vaddinelli, D., Spadano, R., Casciani, P., Papola, F., Lembo, E. D., Iannetti, G., & Bartolomeo, P. D. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01786-4 · Cited by 30
Novel extragenic genomic safe harbors for precise therapeutic T cell engineering
Odak, A., Yuan, H., Feucht, J., Cantu, A., Mansilla‐Soto, J., Kogel, F., Eyquem, J., Everett, J. K., Bushman, F. D., Leslie, C. S., et al. (2023) · Blood · doi:10.1182/blood.2022018924 · Cited by 36
Self-citationDiagnosis and prevention of thalassemia
Ip, H., & So, C. C. (2013) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.847236 · Cited by 30
Lentiviral vector interactions with the host cell
Borsotti, C., Borroni, E., & Follenzi, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.016 · Cited by 30
Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches
Lamsfus‐Calle, A., Daniel-Moreno, A., Ureña-Bailén, G., Raju, J., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100641 · Cited by 30
Chambers, C. B., Gross, J., Pratt, K. L., Guo, X., Byrnes, C., Lee, Y. T., Lavelle, D., Dean, A., Miller, J. L., & Wilber, A. C. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.011 · Cited by 32
Arrayed lentiviral barcoding for quantification analysis of hematopoietic dynamics
Grosselin, J., Sii-Felice, K., Payen, E., Chrétien, S., Roux, D. T., & Leboulch, P. (2013) · Stem Cells · doi:10.1002/stem.1383 · Cited by 28
Self-citationHistorical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy
Kohn, D. B. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.006 · Cited by 30
Yang, K., Guo, W., Ren, T., Huang, Y., Han, Y., Zhang, H., & Zhang, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1183-2 · Cited by 31
Development and clinical translation of ex vivo gene therapy
Wu, X., He, X., Liu, F., Jiang, X., Wang, P., Zhang, J., & Jiang, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.015 · Cited by 31
Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer
Batty, P. A., Fong, S., Franco, M., Sihn, C., Swystun, L. L., Afzal, S., Harpell, L., Hurlbut, D. J., Pender, A., Su, C., et al. (2024) · Blood · doi:10.1182/blood.2023022589 · Cited by 28
Lin, Y., Wan, J., Gao, G., Pan, Y., Ding, S., Fan, Y.-L., Wang, Y., & Jiang, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.010 · Cited by 28
“Although the application of the lentiviral vector for gene transfer brings several concerned issues, such as insertional mutagenesis [16], it has still achieved encouraging results in the recent clinical treatment for several human diseases in various systems [1,5,7].”
BackgroundGene therapy as a new treatment option for inherited monogenic diseases
Boudes, P. F. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.009 · Cited by 29
“After 33 months, he was able to forgo transfusions and leave a quasi normal life [45].”
BackgroundNew updating into hemoglobinopathies
Fucharoen, S., & Winichagoon, P. (2012) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2012.01446.x · Cited by 28
CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells
Kramarzová, K. Š., Osborn, M. J., Webber, B. R., DeFeo, A. P., McElroy, A. N., Kim, C. A., & Tolar, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061269 · Cited by 32
“Moreover, the potential for vector insertional mutagenesis [42,43], clonal dominance [44], and unregulated expression of a DNA repair protein with the potential for apoptotic resistance [45] in the FA pre-malignant phenotype makes gene editing highly desirable.”
Luan, X., Chen, X., Tang, Y., Zhang, J., Gao, X., Ke, H., Lin, Z., & Zhang, X. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.005 · Cited by 29
“In contrast, LVs belong to the class of retroviruses that includes HIV, and are capable of DNA integration in non-dividing cells, including neurons.(27,28) Not showing preferential integration into any specific gene locus, LVs can thus reduce the chances of activating an oncogene in a large number of cells.”
BackgroundAdvances in the gene therapy of monogenic blood cell diseases
Bueren, J. A., Bustamante, O. Q., Almarza, E., Navarro, S., Río, P., Segovia, J. C., & Güenechea, G. (2019) · Clinical Genetics · doi:10.1111/cge.13593 · Cited by 31
Immunoresponse to Gene-Modified Hematopoietic Stem Cells
Drysdale, C. M., Tisdale, J. F., & Uchida, N. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.010 · Cited by 28
“Similarly, in gene therapy trials for SCD and b-thalassemia, rejection of therapeutic bT87Q-globin has not been observed, likely because it differs from intact b-globin by only one amino acid.(7,8)”
BackgroundBzhilyanskaya, V., Ma, L., Liu, S., Fox, L. R., Whittaker, M. N., Meis, R. J., Choi, U., Lawson, A., Ma, M., Theobald, N., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj6779 · Cited by 28
Rittelmeyer, I., Rothe, M., Brugman, M. H., Iken, M., Schambach, A., Manns, M. P., Baum, C., Modlich, U., & Ott, M. (2012) · Hepatology · doi:10.1002/hep.26204 · Cited by 28
“We detected a partial overlap of common insertion sites in these cell types, indicating the presence of cell type-independent ‘‘hot spots’’ for lentiviral integration, which need to be distinguished from selection events.48 Clonal dominance in the hematopoietic system is typically accompanied by vector insertions in p…”
BackgroundKumar, P., Beck, D., Galeev, R., Thoms, J. A. I., Talkhoncheh, M. S., de Jong, I., Unnikrishnan, A., Baudet, A., Subramaniam, A., Pimanda, J. E., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018023986 · Cited by 30
“The notion of benign expansion effects from HMGA2 is further supported by findings from X-SCID and b-thalassemia gene therapy trials where recurrent events of lentiviral vector integration within the HMGA2 locus resulting in increased HMGA2 expression were observed.(16,17) Indeed, it was found that this provided a clo…”
ResultBosma, P. J., Wits, M., & Elferink, R. P. J. O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010273 · Cited by 28
Metadata
- Authors
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chrétien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.-J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chrétien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S., & Leboulch, P.
- Affiliations
- Inserm (FR)
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- University of Trieste (IT)
- Hôpital Intercommunal de Créteil (FR)
- Hôpital Tenon (FR)
- Columbia University Irving Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Indiana University Indianapolis (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7313
- Pages
- 318-322
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3355472
- OpenAlex
- W2136274459
- Cited by
- 1,276
- References
- 32
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 46 · 2023: 53 · 2022: 64 · 2021: 75 · 2020: 76 · 2019: 84 · 2018: 79 · 2017: 97 · 2016: 94 · 2015: 99 · 2014: 94 · 2013: 116 · 2012: 106
- FWCI
- 63.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL090921, HL090921)
- National Institute of Allergy and Infectious Diseases (AI52845, R01AI082020, R01AI052845, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- beta-thalassemia, gene therapy, lentiviral vectors, transfusion independence, HMGA2, leukemia risk, hemoglobinopathies, sickle cell disease, hematopoietic stem cells, alternative splicing, hemoglobin
- MeSH terms
- Adolescent, Blood Cells, Blood Transfusion, Bone Marrow Cells, Child, Preschool, Clone Cells, Genetic Vectors, Homeostasis, Humans, Male, Organ Specificity, RNA, Messenger, Time Factors, Genetic Therapy, Transcriptional Activation, Gene Expression, Lentivirus, beta-Thalassemia, HMGA2 Protein, MicroRNAs, beta-Globins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.